Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk

Abstract

Background: Diabetes and hypertension are risk factors for renal and cardiovascular outcomes. Data on the association of achieved blood pressure (BP) with renal outcomes in patients with and without diabetes are sparse. We investigated the association of achieved SBP, DBP with renal outcomes and urinary albumin excretion (UAE) in people with vascular disease. Methods: In this pooled analysis, we assessed renal outcome data from high-risk patients aged 55 years or older with a history of cardiovascular disease, 70% of whom had hypertension, randomized to The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial and to Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease trials investigating telmisartan, ramipril and their combination with a median follow-up of 56 months. Standardized office BP was measured every 6 months, estimated glomerular filtration rate (eGFR) and UAE at baseline, 2 years and study end. Associations of mean achieved BP on treatment were investigated on major renal outcomes including end-stage renal disease (ESRD), decline of eGFR by at least 40%, doubling of creatinine and the composites thereof and on UAE. Analyses were by Cox regression analysis, analysis of variance and Chi 2-test. Of 30 937 patients with complete data, 19 450 patients without and 11 487 with diabetes were enrolled between 1 December 2001 and 31 July 2003 and followed until 31 July 2008. Data were pooled as the outcomes for telmisartan 80 mg/day (n = 2903) or placebo (n = 2907) for Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease and ramipril 10 mg/day (n = 8407), telmisartan 80 mg/day (n = 8386) or the combination of both (n = 8334) were similar. Results: For both those with and without diabetes, the hazard ratios for the composites ESRD or doubling of serum creatinine (707 events overall) and ESRD or 40% eGFR loss (2371 events overall) reached a nadir at achieved SBP of 120 to less than 140 mmHg, and increased with higher and lower SBP with similar relative risk with or without diabetes. For example, risk for the former composite reached a hazard ratios 3.06 (confidence interval 1.90–4.92) with a mean achieved SBP more than 160 mmHg compared with 120 to less than 130 mmHg with diabetes and hazard ratios 2.14 (1.09–4.26) without diabetes. In contrast, the development of new microalbuminuria and macroalbuminuria (3002 and 846 events overall) associated linearly over the whole range of achieved SBP (apart from a slight increase in risk at SBP less than 120 mmHg only in those without diabetes). Absolute risks for the composite and albuminuria outcomes were consistently greater in those with diabetes as compared with without diabetes with high event rates over the whole SBP spectrum. The increased renal risk at low SBP was not related to a meaningful reduction of mandated study drugs or open label renin–angiotensin–aldosterone system inhibition. Conclusion: In patients at high cardiovascular risk, SBP levels more than 140 mmHg and less than 120 are associated with increased risk for renal outcomes. Renal risk was greater in diabetes across the whole range of achieved SBP and DBP. These data suggest similar target BP range in patients with and without diabetes to prevent renal outcomes, a frequent complication in high-risk vascular patients. Clinical trial registration: Clinical Trial registration: http://clinicaltrials.gov.Unique identifier: NCT00153101.

Overview

Integrity signals

Registry

Crossref · 10.1097/hjh.0000000000002697

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 44 references

Cited by

See all 12

Metadata

Authors
Böhm, M., Schumacher, H., Teo, K. K., Lonn, E. M., Mahfoud, F., Emrich, I., Mancia, G., Redon, J., Schmieder, R. E., Sliwa, K., Lehrke, M., Marx, N., Weber, M. A., Williams, B., Yusuf, S., & Mann, J. F. E.
Affiliations
  • Universitätsklinikum des Saarlandes (DE)
  • Statistical Consultant, Ingelheim, Germany
  • Population Health Research Institute (CA)
  • University of Milano-Bicocca (IT)
  • Hypertension Unit, Hospital Clínico Universitario, University of Valencia, València, Spain
  • Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
  • University of Cape Town (ZA)
  • Universitätsklinikum Aachen (DE)
  • State University of New York (US)
  • National Institute for Health and Care Research (GB)
Corresponding author
Böhm, Michael
Venue
Journal of Hypertension
Published
2021-02-03
Volume
39
Issue
4
Pages
766-774
ISSN
  • 0263-6352 (ISSN-L)
  • 1473-5598
OpenAlex
W3128014409
Cited by
12
References
44
Citations by year
2026: 1 · 2025: 1 · 2024: 3 · 2023: 5 · 2022: 1 · 2021: 1
FWCI
1.67
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Hypertension (publishedVersion)
  • PubMed (publishedVersion)
  • BOA (University of Milano-Bicocca) (submittedVersion)
  • RWTH Publications (RWTH Aachen) (submittedVersion)
Funders
Medical Research Council (MC_PC_13090)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
Keywords
renal outcomes, blood pressure, diabetes mellitus, hypertension, telmisartan, ramipril, urinary albumin excretion, end-stage renal disease, estimated glomerular filtration rate decline, cardiovascular risk, ACE inhibitors, angiotensin receptor blockers, renal protection, antihypertensive therapy, older adults, vascular disease, TRACS
MeSH terms
Heart Disease Risk Factors, Angiotensin-Converting Enzyme Inhibitors, Benzoates, Blood Pressure, Cardiovascular Diseases, Diabetes Mellitus, Humans, Hypertension, Middle Aged, Risk Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk. https://app.cochat.ai/papers/10.1097/hjh.0000000000002697
The paper
Böhm, M., Schumacher, H., Teo, K. K., Lonn, E. M., Mahfoud, F., Emrich, I., Mancia, G., Redon, J., Schmieder, R. E., Sliwa, K., Lehrke, M., Marx, N., Weber, M. A., Williams, B., Yusuf, S., & Mann, J. F. E. (2021). Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk. Journal of Hypertension. https://doi.org/10.1097/hjh.0000000000002697

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.